JeffreyAllanZonderMD

Hematology • Detroit, MI

Hematologic Oncology

Professor of Oncology (Multiple Myeloma and Amyloidosis Specialist)

Join to view full profile

Dr. Zonder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zonder's full profile

Already have an account?

Office
Karmanos Cancer Center
4100 John R Hwcrc 4th Fl
Detroit, MI 48201
Phone+1 800-527-6266

Fax+1 313-576-8767

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
University of RochesterResidency, Internal Medicine, 1995 - 1998
Wayne State University School of MedicineClass of 1995
Duke UniversityBA, Biological Anthropology, Art-Design (Double Major), 1987 - 1991

Certifications & Licensure

MI State Medical License 1998 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Accelerator Award Multiple Myeloma Research Foundation, 2015
School of Medicine Teaching Award Wayne State University, 2005, 2012, 2015
Fellows' Hematology Teaching Award Division of Hematology-Oncology, 2007, 2012

Clinical Trials

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Start of enrollment: 2005 May 01
Completed
Phase 1
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma Start of enrollment: 2006 Dec 01
Completed
Phase 1
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease Start of enrollment: 2007 Sep 01
Completed
Phase 2
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma Start of enrollment: 2008 Oct 01
Terminated
Phase 1
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2009 Oct 01
Completed
Phase 1
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Start of enrollment: 2013 Mar 01
Terminated
Phase 1
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Jun 05
Completed
Phase 1
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Completed
Phase 2
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2016 Dec 28
Completed
Phase 2
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis Start of enrollment: 2017 Aug 25
Active, not recruiting
Phase 2
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma Start of enrollment: 2020 Aug 17
Suspended
Phase 1, Phase 2
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis Start of enrollment: 2021 Apr 28
Recruiting
Phase 1
Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2019 Jan 23
Recruiting
Phase 1, Phase 2
Roles: Contact
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies Start of enrollment: 2021 Aug 17
Completed
Phase 2
Roles: Contact, Principal Investigator
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Start of enrollment: 2022 Mar 07
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2022 Sep 27
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Active, not recruiting
Phase 1
Roles: Principal Investigator
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma Start of enrollment: 2023 Dec 21
Recruiting
Phase 2
Roles: Principal Investigator
Dietary Reporting In The Amyloidoses Start of enrollment: 2023 Mar 02
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
DapagliFLOzin in Renal AL Amyloidosis (FLORAL) Start of enrollment: 2024 May 01
Not yet recruiting
Phase 2
Roles: Sponsor-Investigator
Join now to see all

Publications & Presentations

PubMed

Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff
Leukemia & Lymphoma. 2024-12-01
8 citations
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman
Journal of Clinical Oncology. 2024-08-01
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non- Hispanic White race/ethnicity in the United States.
Tondre Buck, Monique A Hartley-Brown, Yvonne A Efebera, Carter P Milner, Jeffrey A Zonder
Haematologica. 2024-06-01

Abstracts/Posters

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have B...
Jeffrey A. Zonder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Jeffrey A. Zonder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
Jeffrey A. Zonder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
Jeffrey A. Zonder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
Jeffrey A. Zonder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
Jeffrey A. Zonder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
Jeffrey A. Zonder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Untangling Amyloidosis 2019
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Untangling Amyloidosis 2019
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to t...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Untangling Amyloidosis 2018
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

The Uncanny Symptoms That Led to a Detroit Filmmaker’s Multiple Myeloma DiagnosisMay 3rd, 2023
Triple-Drug Therapy for Post-Transplant Management of Multiple MyelomaJanuary 13th, 2023
Expanded Cancer CareNovember 21st, 2022
Join now to see all